02/24/2026
🔬 Exciting new research is emerging around Retatrutide and the scientific community is paying close attention.
Recent preclinical studies published in peer-reviewed journals have revealed some remarkable findings:
🧬 **Tumor Reduction** Low-dose Retatrutide reduced tumor volume by up to 3-fold in preclinical models, showing efficacy comparable to anti-PD-1 immunotherapy.
🦠 **Pancreatic & Lung Cancer** Studies show Retatrutide reduced tumor engraftment rates, delayed tumor onset, and suppressed tumor growth in pancreatic and lung cancer models, with one study reporting a striking 14-fold reduction in pancreatic tumor volume vs. semaglutide.
⚖️ **Obesity-Cancer Link** Research suggests that Retatrutide-mediated weight loss may also reduce cancer risk and improve outcomes, highlighting the powerful connection between metabolic health and cancer progression.
As a triple GIP/GLP-1/Glucagon receptor agonist, Retatrutide continues to be one of the most compelling research compounds being studied today.
At Amnolabs, we're committed to supporting the scientific community with research-grade compounds backed by ≥99% purity and full COA documentation. 🧪
👉 Explore our research catalog: https://www.amnopeptides.com
*For laboratory/research use only. Not for human consumption.*
\
